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ABSTRACT
OBJECTIVE: To verify the effectiveness of screening for tuberculosis (TB) on all-cause mortality 
and tuberculosis cases in newly diagnosed HIV-infected patients through a clinical algorithm 
based on recommendations of the World Health Organization.
METHODS: From March 2014 to April 2016, a pragmatic randomized clinical trial was 
conducted with newly diagnosed and TB-free HIV-infected adults undergoing antiretroviral 
therapy for up to one month at a major tertiary hospital for HIV in the state of Pernambuco, 
Brazil. Participants were randomized into intervention and control groups using an 
automatically-generated random list, and followed-up for at least 6 months. The intervention 
group was screened for TB at hospital admission and at every follow-up visit through a series 
of questions addressing TB-related symptoms (cough, fever, night sweating, and weight loss). 
Patients presenting with any of these symptoms were referred to a pulmonologist and underwent 
sputum smear microscopy, sputum culture, and rapid molecular testing (GeneXpert). When at 
least one test result came back positive, TB treatment was initiated. In turn, if patients tested 
negative but presented with severe clinal symptoms, TB preventive treatment was initiated. 
Screening for TB was not performed systematically in the control group. The primary outcome 
assessed in this study was death from all causes, and secondary outcomes included sensitivity 
and specificity of this screening test, as well as its detection time.
RESULTS: This study evaluated 581 patients, 377 in the intervention group (64.9%) and 204 in 
the control group (35.1%). In total, 36 patients died during the follow-up period. Of these, 26 
(6.9%) were from the intervention group, reaching a cumulative mortality coefficient of 69 per 
1,000 inhabitants, and 10 (4.9%) from the control group (p = 0.341), with a cumulative mortality 
coefficient of 49 per 1,000 inhabitants (p = 0.341).
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INTRODUCTION
The synergy between the human immunodeficiency virus (HIV) and Mycobacterium 
tuberculosis has been a major threat for public health due to its magnitude and the high 
mortality rates from tuberculosis (TB) among people living with HIV (PLHIV). Nowadays, 
about 10% of TB cases worldwide are estimated to occur among PLHIV, while 22% of deaths 
due to TB are attributed to TB-HIV coinfection1. Studies have shown that an early diagnosis 
and treatment for tuberculosis may help reducing such rate among PLHIV2,3. The negative 
outcomes related to tuberculosis are enhanced before co-infection with TB-HIV, often 
resulting from late diagnosis due to the lower sensitivity of diagnostic tests (low bacilli 
load in biological samples) and poor treatment response4–7. 
According to the World Health Organization (WHO), screening for TB in PLHIV should be 
performed through a clinical algorithm addressing symptoms often related to the condition, 
such as cough of any duration, fever, night sweats, and weight loss. Patients presenting at 
least one of these symptoms must be further investigated by undergoing specific tests8. 
However, recent studies have presented inconclusive results depending on the region 
where they are performed9–17. In this sense, our study aims is to verify the effectiveness of a 
screening test for TB performed through a clinical algorithm among PLHIV in the routine 
of a specialized health service in HIV, verifying its impact on all-cause mortality.
METHODS
Trial Design
This is a pragmatic randomized clinical trial conducted in a public health service in Recife/
Pernambuco. To verify the real impact of the intervention, this design is recommended for 
studies evaluating the routine of care teams in health services. The intervention group was 
attended by five doctors and nurses trained for TB screening. Individuals were allocated to 
the intervention group in a 2:1 ratio in relation to the control group.
This study was conducted according with the CONSORT guidelines for pragmatic trials.
Changes to Methods after Trial Commencement
As the hospital where our trial was conducted was the major service for HIV/AIDS in the state 
of Pernambuco, our study considered a larger sample at first. However, the decentralization 
policy enabled patients to receive care in health services near their residences, so that the 
number of newly diagnosed HIV-positive patients drastically reduced in the service in 
question. To achieve the research objectives, we had to redesign the sample.
Participants
Our study population comprised newly diagnosed HIV-positive adult patients with either 
no previous record of or one-month antiretroviral therapy (ART), and with no history of 
diagnosis or treatment of TB during the past three months. These patients were treated and 
recruited between March 2014 and April 2016 in the outpatient clinic of the Correia Picanço 
Hospital (CPH) – a referral center for people living with HIV responsible for treating around 
50% of AIDS and HIV-infected individuals in the Pernambuco state, Northeastern Brazil. 
Participants were treated by spontaneous demand or referred from other health services 
or from CPH emergency department and ward. Incarcerated patients were excluded due 
to the difficulties in follow-up.
Interventions
Trained nurses administered a standardized questionnaire to both groups (control and 
intervention) at hospital admission, collecting socioeconomic and lifestyle data, as well as 
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information on previous TB episodes. As recommended by the WHO, a second questionnaire 
was applied to collect data on symptoms related to tuberculosis, such as cough, fever, night 
sweats, and weight loss. Participants presenting with at least one of these symptoms were 
referred to a pneumologist and underwent TB investigation through clinical assessment 
and chest X-ray (before the impossibility of providing at least 2 mL of sputum) or sputum 
smear microscopy, sputum culture, and GeneXpert MTB/RIF (when patients were able to 
provide a one-spot sputum of at least 2mL). 
Patients with at least one positive result for sputum smear test or GeneXpert MTB/RIF 
were classified as bacteriologically confirmed TB cases and initiated treatment for TB. 
In turn, patients with chest X-ray results indicative of TB and/or presenting criteria for 
clinical severity (anemia, CD4+ T-cell lymphocyte count < 200 cells/mm3, and BMI < 18,5), 
were classified as presumptive TB and initiated empirical therapy. All patients undergoing 
treatment for TB were followed up by both a pneumologist, responsible for assessing the 
progress of tuberculosis treatment, and by an infectologist, responsible for assessing the 
progress of HIV/AIDS treatment.
Patients in the intervention group who presented with no tuberculosis-related symptoms 
at screening and those whose tests results came back negative for both confirmed or 
presumptive TB were followed up by an infectologist and underwent the same clinical 
screening for TB at every follow-up visit. Considering that the health status of these patients 
could eventually deteriorate, leading them to search for care in other services where they 
could be diagnosed with TB or even die, we consulted the medical records made available 
by other health services in search for these cases. 
The control group comprised patients following the routine of the Health Service, so that 
the disease investigation was left to the discretion of physicians.
Outcomes
The primary outcome evaluated in our study was death from all causes, and secondary 
outcomes included tuberculosis cases. Outcomes were obtained by probabilistic linkage 
between data collected in our research and mortality records related to Pernambuco, 
obtained from the Mortality Information System (SIM). TB cases were identified by 
establishing an association between our data and that from the Information System for 
Notifiable Disease (Sinan).
Sample Size
Sample size was calculated based on the proportion of deaths between the exposed 
(intervention) and the non-exposed group (control). Determined from the 2014 approximate 
mortality rate due to HIV in Pernambuco (6.2%)19, we estimated a 7% death from the 
disease for the PLHIV population. Individuals were grouped into exposed and non-exposed 
considering a 2:1 ration, and we adopted a 80% study power, 95% confidence interval (CI), 
and a 5% alpha error. With that, we reached a sample size qual to 483 patients – 322 in the 
intervention group and 161 in the control group.
Randomization
For randomization, we used a series of sealed envelopes containing a computer-generated 
number of 0 or 1, which were opened sequentially when the patient was included in the 
study. Randomization sequence, participants registration, and interventions were performed 
by the project team (coordinator, field coordinator, auxiliaries, nurses, and physicians).
After the first consultation with the nursing staff at the CPH outpatient clinic, patients 
were invited to participate in the study. On this occasion, patients were informed about the 
purpose of the study, and those who agreed to participate were requested to sign an informed 
consent form (ICF). Then, patients were randomized into intervention and control groups.
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Follow-Up
Once randomized into control and intervention groups, participants underwent two 
monthly follow-up visits at CPH. The last patient entered the study in April 2016, and the 
final follow-up session was held in October 2016.
Data on mortality and TB diagnosis were obtained from medical records and associated with 
the Information System for Notifiable Diseases (Sinan TB) and the Mortality Information 
System (SIM) for the state of Pernambuco using the RecLink III software11.
Statistical Methods
All data analyses were performed using the Stata 15 software. The primary outcome – death 
from all causes – was determined by survival analysis and Kaplan-Meier estimator, and 
survival curves were compared using the Z statistics obtained with the log-rank test. Follow-up 
period was considered as the time between diagnosis and death (failure) or, for surviving cases 
(censorship), as the time between diagnosis and the completion of the six-month follow-up. 
The secondary outcome – TB diagnosis – was obtained by comparing the number of cases 
notified in both intervention and control group. The accuracy of the screening method 
for TB was measured based on sensitivity, specificity, positive predictive value (PPV), 
and negative predictive value (NPV). We also evaluated screening effectiveness for the 
combination between chest X-ray and clinical algorithm assessing signs and symptoms 
related to TB, such as fatigue, shortness of breath, presence of lump, or body pain (Table 1). 
Considering both confirmed and empirical cases, the cumulative incidence of TB was 
compared between intervention and control group, as well as the cure proportion at the 
end of the treatment. Case severity was analyzed based on the occurrence of unfavorable 
outcomes (abandonment and death). 
We calculated the median time between HIV diagnosis and clinical suspicion of TB; 
clinical suspicion of TB and TB treatment initiation; and HIV diagnosis and TB treatment 
initiation. Clinical suspicion was considered as the date corresponding to smear 
microscopy, sputum culture or GeneXpert examination request or the date indicated in 
the medical record as TB-related symptoms onset. Cumulative incidence was calculated 
by dividing confirmed cases by the total number of cases in each group. 
The p-value obtained by Chi-square test was used to verify statistically significant differences 
between the groups. Means were compared using the T-student test, and medians using 
the Kruskal-Wallis test.
Alpha values equal to 0.05 were considered as statistically significant.
Ethical Aspects
This study was conducted according with the Guidelines and Regulatory Standards for 
Research Involving Human Subjects, established by the Resolution No. 466 of December 
12, 2012 of the National Health Council21. The project was approved by the Research Ethics 
Committee of the Aggeu Magalhães Research Center, Fiocruz-PE, No. 279.324. The clinical 
trial was approved by the Brazilian Registry of Clinical Trials (ReBEC), under registration 
number RBR-22t943.
RESULTS
Among the 663 eligible patients admitted to the Correia Picanço Hospital (CPH) during 
the study period, 82 (12.4%) were excluded – 72 (87.8%) of whom refused to participate and 
10 (12.2%) who were excluded for presenting negative HIV test results (n = 5) or for being 
incarcerated (n = 5). Thus, our study sample comprised 581 patients: 377 (64.9%) in the 
intervention group and 204 (35.1%) in the control group (routine) (Figure 1).
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Regarding sample characterization, most participants were male (71.8%), with a mean 
age of 35 years (minimum 18 and maximum 71 years); 63.3% were residents in Recife, 
the state capital, and almost 10% were illiterate and presented with a low CD4 count. 
Socioeconomic and clinical characteristics were similar in both groups, indicating the 
efficacy of the randomization.
Clinical algorithm-based screening for tuberculosis (TB) showed a moderate sensitivity (85.3%) 
and low specificity (46.4%), reaching a very low positive predictive value (PPV; 13.6%), but a high 
Table 1. Prevalence, predictive values, sensitivity, and specificity of TB-related symptoms and other screening factors, Recife, 2014–2016.
TB-related Symptoms 




Sensitivity Specificity PPV PNV
Cough 30 (25.4–34.9) 71 (52.5–84.9) 70.6 (53.9–83.2) 74.1 (69.2–78.4) 21.2 (14.7–29.7) 96.2 (93.2–97.9)
Fever 18.9 (15.1–23.) 50 (32.4–67.6) 50 (34.1–65.9) 84.2 (80.0–87.7) 23.9 (15.5–35.0) 94.4 (91.3–96.5)
Night sweats 12.8 (9.6–16.6) 29.4 (15.1–47.5) 29.4 (16.8–46.2) 88.9 (85.1–91.8) 20.8 (11.7–34.3) 92.7 (89.3–95.0)
Weight loss 47.9 (42.7–53.1) 82.4 (65.5–93.2) 82.4 (66.5–91.7) 55.6 (50.3–60.7) 15.6 (11.0–21.6) 96.9 (93.5–98.6)
WHO’s Screening 56.5 (51.3–61.3) 85.3 (68.9–95.0) 85.3 (69.9–93.6) 46.4 (41.2–51.6) 13.6 (9.7–18.9) 97.0 (93.1–98.7)
Other TB-related symptoms 
Shortness of breath 18.4 (14.6–22.6) 35.3 (19.7–53.5) 35.3 (21.5–52.1) 83.3 (79.0–86.9) 17.4 (10.2–28.0) 92.8 (89.4–95.2)
Weakness 38.6 (33.6–43.7) 70.6 (52.5–84.9) 70.6 (53.8–83.2) 64.6 (59.4–69.5) 16.6 (11.4–23.5) 95.7 (92.2–97.6)
Chest or back pain 20.7 (16.8–25.2) 44.1 (27.2–62.1) 44.1 (28.9–60.6) 81.6 (77.1–85.3) 19.2 (12.0–29.3) 93.6 (90.3–95.9)
Lump 15.7 (12.2–19.8) 26.5 (12.9–44.4) 26.5 (14.6–43.1) 85.4 (81.2–88.7) 15.3 (8.2–26.5) 92.1 (88.6–94.6)
Other symptoms combination 
WHO’s screening + chest X-ray 58.6 (53.5–63.6) 85.3 (68.9–95.0) 85.3 (69.9–93.6) 44.0 (38.9–49.3) 13.1 (9.3–18.2) 96.8 (92.7–98.6)
At least 2 WHO’s screening 33.0 (28.2–38.0) 82.4 (65.5–93.2) 82.4 (66.5–91.7) 71.9 (66.9–76.4) 22.6 (16.1–30.7) 97.6 (94.9–98.9)
At least 3 WHO’s screening 15.4 (11.9–19.5) 54.9 (35.1–70.2) 52.9 (36.7–68.6) 88.3 (84.5–91.3) 31.0 (20.6–43.8) 95.0 (92.0–96.9)
At least 4 WHO’s screening 4.8 (2.9–7.5) 8.8 (1.9–23.7) 8.8 (3.0–23.0) 95.6 (92.9–97.3) 16.7 (5.8–39.2) 91.3 (88.0–93.8)
Cough + Fever 1.3 (0.4–3.1) 0 (0–10.3) 0 (0–1.2) 98.5 (96.6–99.4) 0 (0–43.5) 89.6 (86.1–92.3)
Cough + Night sweats 0.5 (0–1.9) 0 (0–10.3) 0 (0–1.2) 99.4 (97.9–99.8) 0 (0–65.8) 90.9 (87.6–93.4)
Cough + Weight loss 9.3 (6.6–12.7) 17.6 (6.7–34.5) 17.7 (8.3–33.5) 91.5 (88.1–94.0) 17.1 (8.1–32.7) 91.8 (88.4–94.3)
Fever + Night sweats
Fever + Weight loss 4.5 (2.7–7.1) 5.9 (0.7–19.7) 5.9 (1.6–19.1) 95.6 (92.9–97.3) 11.8 (3.3–34.3) 91.1 (87.7–93.6)
Night sweating + Weight loss 1.9 (0.7–3.8) 5.9 (0.7–19.7) 5.9 (1.6–19.1) 98.5 (96.6–99.4) 28.6 (8.2–64.1) 91.3 (88.0–93.8)
Cough + Fever + Night sweats 0.2 (0–1.4) 2.9 (0–15.3) 2.9 (0.5–14.9) 100 (98.9–100) 100 (20.7–100) 91.2 (87.9–93.7)
Cough + Fever + Weight loss 5.6 (3.5–8.4) 29.4 (15.1–47.5) 29.4 (16.8–46.2) 96.8 (94.3–98.2) 47.6 (28.3–67.6) 93.2 (90.1–95.4)
Cough + Night sweats + Weight 
loss
2.4 (1.1–4.5) 2.9 (0–15.3) 2.9 (0.5–14.9) 97.7 (95.5–98.8) 11.1 (2.0–43.5) 91.0 (87.6–93.5)
WHO’s screening + Shortness of 
breath
15.4 (11.9–19.5) 32.4 (17.4–50.5) 32.4 (19.1–49.1) 86.2 (82.2–89.5) 19.0 (10.9–30.9) 92.8 (89.4–95.1)
WHO’s screening + Weakness 32.2 (27.5–37.2) 64.7 (46.5–80.3) 64.7 (47.9–78.5) 71.1 (66.0–75.6) 18.2 (12.3–26.0) 95.3 (92.0–97.3)
WHO’s screening + Chest or 
back pain
18.4 (14.6–22.6) 44.1 (27.2–62.1) 44.1 (28.9–60.6) 84.2 (80.0–87.7) 21.7 (13.6–32.8) 93.8 (90.5–96.0)
WHO’s screening + Lump 10.6 (7.7–14.2) 23.5 (10.7–41.2) 23.5 (12.4–40.0) 90.6 (87.1–93.3) 20 (10.5–34.8) 92.3 (88.9–94.7)
WHO’s screening + Shortness of 
breath + Weakness + Chest or 
back pain + Lump
2.4 (1.1–4.5) 11.8 (3.3–27.5) 11.8 (4.7–26.6) 98.5 (96.6–99.4) 44.4 (18.9–73.3) 91.8 (88.6–94.2)
WHO’s screening + At least one 
signal (shortness of breath or 
weakness or pain or lump)
41.8 (36.7–46.9) 67.6 (49.5–82.6) 67.7 (50.8–80.9) 60.8 (55.6–65.8) 14.7 (10.0–21.0) 95.0 (91.2–97.2)
WHO’s screening considering 
only cough for more than 2 
months
52.4 (47.2–57.5) 85.3 (68.9–95.0) 85.3 (69.9–93.6) 50.9 (45.6–56.1) 14.7 (10.5–20.3) 97.2 (93.6–98.8)
TB: tuberculosis; PPV: positive predictive value; PNV: negative predictive value; WHO: Wolrd Health Organization.
Note: WHO’s screening refers to the screening method recommended by the World Health Organization.
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negative predictive value (NPV; 97%). Amongst the various symptom combinations tested, 
that recommended by the World Health Organization (WHO) provided the most satisfactory 
results – although not considered excellent. Screening performance remained the same after 
chest X-ray inclusion, with a 44% specificity, a 13.1% PPV, and a 96.8% NPV (Table 1).
We identified 53 cased of TB during follow-up, 34 in the intervention group and 19 in the 
control group. Both groups showed similar TB cumulative incidences: 9% for the intervention 
(95% CI: 6.3%–12.4) and 9.3% for the control (95% CI: 5.7%–14.2%) (p = 0.906).
We detected seven (20.6%) bacteriologically confirmed TB cases in the intervention group 
and two (10.5%) in the control group, showing a statistically non-significant difference 
(p = 0.297). Pulmonary TB was the predominant form of the disease in both groups, 
especially the intervention group (52.9% vs. 42.1% in the control group), but without 
significant difference (p = 0.748). A “cure” outcome occurred in ten (30.3%) of the 34 
confirmed cases of TB in the intervention group and in nine cases of the control group 
(50%), without statistically significant difference (p = 0.454) (Table 2).
Both groups showed a similar median time between HIV diagnosis and clinical suspicion 
of TB, with one day in the intervention group (IQR = 0–5 days) and 25 days in the control 
group (IQR = 5.5–69) (p = 0.093). 
The median time between clinical suspicion of TB treatment initiation was 29 days 
(IQR = 14–75 days) for the intervention group and 51.5 days (IQR = 7.5–122) for the control 
group (p = 0.864).
Likewise, the median time between HIV diagnosis and TB treatment initiation was 
similar between groups, with 40 days (IQR = 18–77) in the intervention group and 50 days 
(IQR = 15–75 days) in the control group, without statistically significant difference (p = 0.978).
A total of 36 deaths occurred during the follow-up period – 26 (6.9%) in the intervention 
group and 10 (4.9%) in the control group (p = 0.341), – with an overall cumulative mortality 
equal to 62 deaths per 1,000 inhabitants. Corresponding cumulative mortality was 69 per 
1,000 inhabitants in the intervention group and 49 per 1,000 inhabitants in the control 
group (p = 0.341). 
Ten of the 36 deaths recorded in the study were related to TB – six in the intervention and 
four in the control group. Thus, TB mortality rate was 17.2 per 1,000 inhabitants in the 
overall study population, 18.6 per 1,000 in the intervention group, and 14.7 per 1,000 in the 
control, without statistical difference (p = 0.705). Treatment abandonment was also similar 
between groups, with 21% in the intervention and 18% in the control (p = 0.761).
The follow-up time for the entire cohort was 175.9 days. Total person-years at risk was equal 
to 266, and the all-cause mortality rate was 1.4 per 100 person-years. Figure 2 presents the 
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Table 2. Characteristics of tuberculosis (TB) cases, detection, and death between Intervention and 
Control groups, Recife, 2014–2016.
Intervention group Control group
p
n (%) n (%)
Tuberculosis
No 343 (91.0) 185 (90.7) 0.906
Yes 34 (9.0) 19 (9.3)
Total 377 204
Form of TB
Pulmonary 18 (52.9) 8 (42.1)
Extrapulmonary 9 (26.5) 6 (31.6) 0.748
Disseminated 7 (20.6) 5 (26.3)
Total 34 19
Confirmed Tuberculosis 
Yes 7 (20.6) 6 (31.6) 0.372
No 27 (79.4) 13 (68.4)
Total 34 19
TB Outcome 
Cure 10 (30.3) 9 (50.0) 0.164
Others 23 (69.7) 9 (50.0)
Total 33 18
Death
No 351 (93.1) 194 (95.1) 0.341
Yes 26 (6.9) 10 (4.9)  
Total 377 204
TB cases Characteristics 
Time in days of diagnosis (mean) 49.9 54.6 0.967
Exams performed
Sputum smear 17 (81.0) 4 (19.0) 0.228a
GeneXpert 3 (60.0) 2 (40.0) 0.400a
Culture 7 (87.5) 1 (12.5) 0.875a
Chest X-ray 11 (64.7) 6 (35.3) 0.353a
Total 38 13
Positive exams
Sputum smear 2 (50.0) 2 (50.0) 0.228a
GeneXpert 3 (100.0) 0 (0.0) 0.400a
Culture 1 (100.0) 0 (0.0) 0.875a
Chest X-ray 5 (31.3) 1 (16.7) 0.353a
Total 11 3
Diagnostic site
CPH 26 (68.4) 12 (31.6) 0.358a
Other services 5 (55.6) 4 (44.4)
Total 31 16
Location of diagnosis in CPH
Outpatient care 17 (70.8) 7 (29.2) 0.602a
Inpatient care 9 (69.2) 4 (30.8)
Total 26 11
ART
Yes 28 (66.7) 14 (33.3) 0.342a
No 6 (54.6) 5 (45.5)  
Total 34 19
CPH: Correia Picanço Hospital; ART: antiretroviral therapy.
a p-value of the chi-square test or exact Person test.
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Kaplan-Meier Curve for the probability of overall survival in the first six months after HIV 
diagnosis, reaching a 94% probability by the end of follow-up. Regarding the values for each 
group, mean follow-up time was 175 days for the intervention and 177.4 for the control; 
total person-years at risk was 172.3 for the intervention group and 93.7 for the control; and 
mortality rate was 15.1 per 100 person-years for the intervention and 10.7 per 100 person-
years for the control. The Kaplan-Meier probability of overall survival in the first six months 
was 93.1% in the intervention and 95.1% in the control group, without statistically significant 
differences from the log-rank test (p = 0.343) (Figure 2).
DISCUSSION
This pragmatic clinical trial demonstrates that the clinical algorithm-based screening 
method for tuberculosis (TB) recommended by the World Health Organization (WHO) 
shows moderate sensitivity and low specificity. Intervention and control group showed no 
differences regarding TB cases detection and outcomes (abandonment and death), as well 
as for the overall survival. 
Figure 2. Kaplan-Meier curve for the overall survival probability in the first six months after HIV diagnosis.
0.5
0 200 400 600 800 1000
Analysis time
95% Cl Survival rate
0.5
0 200 400 600 800 1000
Analysis time
95% Cl 95% Cl
InterventionControl
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The screening method reached a high negative predictive value (NPV) – an important factor 
for clinical care given that HIV-infected patients who report no cough, fever, night sweats, 
and weight loss most likely do not present with TB (97%).
Our results also indicate that the period between HIV diagnosis, clinical suspicion of 
TB, TB treatment initiation were lower in the intervention group when compared to the 
control group. If we were able to properly certify the dates of clinical suspicion of TB in the 
control group, these differences could be greater. Few TB-related tests were requested for 
participants in this group, and we verified the lack of specific registry referring to suspected 
TB in most medical records. Some cases did contain notes on the presence of cough, fever, 
or weight loss symptoms, but no record of requested tests. In this sense, standardizing the 
record of TB-related symptoms would lead physicians to standardize the search for TB.
According to the WHO, the time interval between clinical suspicion of TB and treatment 
initiation could have been even shorter in the intervention group if GeneXpert MTB/RIF 
exams were performed at the health facility9. A study conducted in South Africa showed 
that GeneXpert MTB/RIF delays speeds up TB diagnosis when compared to the standard 
procedure (smear microscopy)22. 
Although several studies have evaluated TB screening procedures in people living with HIV 
(PLHIV) based on the guidelines established by the WHO9–17, none of these were conducted 
exclusively in Brazil. In this sense, analyzing different scenarios with different prevalence 
is extremely important for characterizing the effectiveness of screening for TB in different 
populations9, especially because PPV and NPV may change according with changes in the 
prevalence of TB.
The main indicators of TB screenings for population are sensitivity and specificity; in 
turn, PPV and NPV are the major focus in clinical practice. The values found in our study 
population are similar to those reported in a study conducted by Getahun et al. (2011)9 – 
NPV equal to 97.7% for a 5% prevalence. However, other studies found lower PPV for TB 
screening10. High NPV values contribute to one of the goals proposed by the WHO, namely 
ruling out active TB disease for initiating preventive treatment9. 
Several studies found unacceptable sensitivity and specificity values for symptom-based 
TB screening in certain scenarios, especially regarding the number of false positives due to 
comorbidities including similar symptoms.9,13,14,17 These findings reinforce the need for a more 
effective TB screening in PLHIV. In Brazil, specialized health services for HIV/Aids have highly-
trained professionals who follow the guidelines established by the Ministry of Health and 
made available through manuals and regulations incorporated into health service routines24.
Most studies approaching TB screening sought to evaluate only bacteriologically confirmed 
cases – either by sputum smear microscopy, sputum culture, or GeneXpert10,11,13,15,17. 
Considering that analyzing solely confirmed cases would restrict the study sample to 
individuals able to provide sputum, and acknowledging that PLHIV produce and release 
little sputum, we used TB screening to detect both confirmed and presumed cases of TB. 
Moreover, a study based on the positivity of bacteriology would be unfeasible before the 
insufficient structure of the CPH to induct sputum release.
As increasing cases of presumptive TB have been reported worldwide, accounting for nearly 
half of the total cases, we sought to analyze TB screening amongst presumptive TB, thus 
requiring screening methods based on clinical-epidemiological criteria24. In severe cases, 
TB treatment is often initiated without tests results. Although some studies have shown that 
other symptoms may be related to extrapulmonary TB, studies on screening effectiveness 
often focus primarily on pulmonary TB9. Given that extrapulmonary TB is responsible for 
around 15% of cases in PLHIV worldwide and that in some regions this value exceeds 20%, 
screening methods should consider extrapulmonary TB.
Different from previous studies on the topic, our study considered the impact of screening 
for TB treatment outcomes. However, we found no significant differences in the mortality 
10
Effectiveness of screening for TB in HIV Santos ML et al.
https://doi.org/10.11606/s1518-8787.2021055002936
rate (nor in other treatment outcomes) for both intervention and control groups. This 
finding may be explained by the low impact of screening in the routine of the service or by 
the organization of its healthcare team, which includes trained professionals who follow 
the recommendations established by the WHO.
Our study has some limitations. Firstly, the infrastructure of the Correia Picanço Hospital 
(CPH) lacked medical devices for performing chest X-rays (which could have positively 
impacted screening) and GeneXpert test, thus delaying cases confirmation. Confirmed cases 
of tuberculosis may also have been underreported by the Information System for Notifiable 
Diseases (Sinan), which we attempted to circumvent by using the state-wide database. Moreover, 
the infectologists were divided by study group, so that it was not possible to blind them.
On the other hand, our results advance knowledge to the study field. By evaluating the 
effectiveness of TB screening through a pragmatic clinical trial, we verified that performing 
an additional interview for detecting TB at every follow-up visit to the tertiary service is 
not necessary. Rather, attending physicians could incorporate this procedure into their 
routine care at the specialized services for PLHIV. Considering that other tertiary services 
for HIV/AIDS in the country are likely to present the same reality, our findings may be 
generalized for them. 
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